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Abstract
Objective
To provide an overview of clinical and MRI characteristics of the different variants of the
leukodystrophy megalencephalic leukoencephalopathy with subcortical cysts (MLC) and
identify possible differentiating features.
Methods
We performed an international multi-institutional, cross-sectional observational study of the
clinical and MRI characteristics in patients with genetically confirmed MLC. Clinical in-
formation was obtained by questionnaires for physicians and retrospective chart review.
Results
We included 204 patients with classic MLC, 187 of whom had recessive mutations in MLC1
(MLC1 variant) and 17 in GLIALCAM (MLC2A variant) and 38 patients with remitting MLC
caused by dominant GLIALCAM mutations (MLC2B variant). We observed a relatively wide
variability in neurologic disability among patients with classic MLC. No clinical differences
could be identified between patients with MLC1 andMLC2A. Patients with MLC2B invariably
had a milder phenotype with preservation of motor function, while intellectual disability and
autism were relatively frequent. Systematic MRI review revealed no MRI features that distin-
guish between MLC1 and MLC2A. Radiologic improvement was observed in all patients with
MLC2B and also in 2 patients with MLC1. In MRIs obtained in the early disease stage, absence
of signal abnormalities of the posterior limb of the internal capsule and cerebellar white matter
and presence of only rarefied subcortical white matter instead of true subcortical cysts were
suggestive of MLC2B.
Conclusion
Clinical and MRI features did not distinguish between classic MLC withMLC1 orGLIALCAM
mutations. Absence of signal abnormalities of the internal capsule and cerebellar white matter
are MRI findings that point to the remitting phenotype.
CME Course
NPub.org/cmelist
From the Department of Child Neurology and Amsterdam Neuroscience (E.M.C.H., F.C., D.F.v.R., N.I.W., M.S.v.d.K.), VU University Medical Center, Amsterdam, the Netherlands;
Division of Child Neurology, Department of Neurology, Istanbul Faculty of Medicine (P.T., Z.Y.), and Division of Child Neurology, Department of Neurology, Cerrahpasa Medical
School (C.Y.), Istanbul University; clinical geneticist in private practice (U¨.Ç.), Merkez Mahallesi, I˙stanbul, Turkey; Kariminejad-Najmabadi Pathology & Genetics Center (A.R., A.K.),
Tehran, Iran; Department of Pediatric Neurology (J.P.), School of Medicine in Katowice, Medical University of Silesia, Katowice, Poland; Department of Neuropediatrics (V.M.B.),
Children’s Hospital Zagreb, School of Medicine, University of Zagreb, Croatia; and Department of Functional Genomics (M.S.v.d.K.), Center for Neurogenomics and Cognitive Research,
Amsterdam Neuroscience, VU University, Amsterdam, the Netherlands.
Coinvestigators are listed at links.lww.com/WNL/A357.
Go to Neurology.org/N for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.
The Article Processing Charge was funded by VU University Medical Center.
This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading
and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
Copyright © 2018 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. e1395
Megalencephalic leukoencephalopathy with subcortical
cysts (MLC) is an infantile-onset inherited disorder char-
acterized by cerebral white matter edema.1–3 MRI shows
diffuse signal abnormalities of the cerebral hemispheric
white matter. The swelling of the abnormal cerebral white
matter is most prominent in the first few years of life.1
Subcortical cysts are typically located in the anterior tem-
poral region and less consistently elsewhere.4 Two different
MLC phenotypes can be distinguished: a classic, de-
teriorating phenotype, and a remitting phenotype.5 Classic
MLC is caused by recessive mutations in the MLC1 gene
(MIM 605908) in the majority of cases: this variant is called
MLC1 (MIM 604004).6 Classic MLC caused by recessive
GLIALCAM mutations (also known as HEPACAM, MIM
613925) is called MLC2A.6 Patients with remitting MLC or
MLC2B (MIM 613926) have dominant GLIALCAM
mutations.7 Classic MLC starts with increasing macro-
cephaly in the first year of life; after a few years, patients
develop neurologic signs, most commonly ataxia, spasticity,
and epilepsy.1 Mortality is thought to be low, although no
systematic study on survival has been performed. Remitting
MLC initially resembles classic MLC: patients generally
present with progressive macrocephaly and may have de-
velopmental delay, but neurologic deterioration does not
occur and the MRI abnormalities improve or normalize.
Among patients with MLC1, a relatively broad variation in
disease severity has been described, also for siblings and un-
related patients with the same mutations.8,9 So far, no clinical
differences have been recognized between patients with
MLC2A vs MLC1. It is unknown whether MRI features allow
distinction among MLC1, MLC2A, and MLC2B before im-
provement occurs in the latter. MLC is a rare disorder and
large studies on the disease course are scarce.8,10,11 Systematic
review of MRI characteristics has not been performed. The
objective of the current study is to identify potential different
and perhaps discriminating clinical and MRI features for dif-
ferent MLC variants, aiming at improved clinical recognition
and avoidance of unnecessary genetic testing.
Methods
Study design
We performed an international, cross-sectional observa-
tional multicenter study among all patients with genetically
proven MLC enrolled in the Amsterdam database of
leukoencephalopathies between January 1991 and January
2017. The database contains patients from over the world
referred to VU University Medical Center for MRI review
and mutational analysis. A prerequisite for genetic testing
was review of clinical and MRI data in Amsterdam.1 We
performed analysis of the MLC1 gene as previously de-
scribed,12 if necessary including analysis of MLC1 copy
DNA12 and multiplex ligation-dependent probe amplifica-
tion.13 Analysis of the GLIALCAM gene was also performed
as previously described.7 By DNA analysis in the parents, we
confirmed that recessive variants were biallelic.
Standard protocol approvals, registrations,
and patient consents
We received approval from the ethical standards committee
for clinical evaluation, systematic MRI review, and review of
the DNA findings and obtained informed consent from the
patients/guardians.
Clinical information
We analyzed clinical information available at the start of the
study, supplemented by information obtained via a clinical
questionnaire for physicians. We focused on measures that
could be retrospectively assessed, including head circumfer-
ence, motor deterioration (especially loss of ambulation),
seizures, and death. As formal, standardized assessment of
motor and cognitive development, autistic features, behav-
ioral problems, and current cognitive function was not feasi-
ble, these items were subjectively assessed by physicians and
caretakers or derived from medical records. The patients’
status at last examination was assessed by quantitative, vali-
dated, and widely used 5-level classification systems for gross
motor function (Gross Motor Function Classification System
[GMFCS]), manual ability (Manual Ability Classification
System [MACS]), and communication function (Commu-
nication Function Classification System [CFCS]).14 Scores
on these scales range from I (no limitations) to V (severe
limitations; table e-1, links.lww.com/WNL/A356). Patients
with comorbidities affecting neurologic function were ex-
cluded from the study.
MRI scoring
We scored all available MRIs according to a standardized
protocol.15 Specifically, cysts were defined as areas with the
same signal intensity of CSF on all pulse sequences including
fluid-attenuated inversion recovery, while in rarefaction the
signal intensity was close but not the same.16
Glossary
CFCS = Communication Function Classification System; GMFCS = Gross Motor Function Classification System; MACS =
Manual Ability Classification System; MLC = megalencephalic leukoencephalopathy with subcortical cysts; MLC1 = classic
megalencephalic leukoencephalopathy with subcortical cysts caused by recessive MLC1 mutations; MLC2A = classic
megalencephalic leukoencephalopathy with subcortical cysts caused by recessive GLIALCAM mutations;MLC2B = remitting
megalencephalic leukoencephalopathy with subcortical cysts caused by dominant GLIALCAMmutations; SUDEP = suspected
sudden unexpected death in epilepsy.
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Statistical analysis
We used summary statistics to describe the clinical character-
istics. Results were reported by means ± SD for continuous
variables that were normally distributed, and median with 25th
and 75th percentiles for non-normally distributed data and
ranges. We performed time-to-event analysis of the events “start
of motor deterioration,” “start of cognitive decline,” “first sei-
zure,” “loss of walking without support,” “loss of walking with or
without support,” and “death,” with age as time variable. Indi-
viduals in whom the respective event had not occurred at the last
follow-up were indicated as censored for the respective analysis.
Nonambulatory patients younger than 18 months were not in-
cluded in the analysis of loss of ambulation. We estimated the
median ages at which the events had occurred by plotting
Kaplan-Meier curves. Group differences regarding disease vari-
ant were analyzed with the log-rank test. We performed linear
regression analysis to compare GMFCS, MACS, and CFCS
scores in relation to age per disease variant. Statistical analysis
was performed using SPSS version 22 (IBM, Armonk, NY) and
GraphPad Prism version 6.07 (San Diego, CA).
Results
Patients
A total of 245 patients with MLC from 207 families were di-
agnosed with MLC by DNA analysis. Three patients were ex-
cluded because of comorbidity (Turner syndrome, asphyxia,
pituitary adenoma). In the case of limited clinical information due
to loss to follow-up or nonresponse, patients were selectively
included in the analyses on the basis of availability of information.
Throughout the Results sectionwe report the number of patients
included in the different analyses in parentheses or in the re-
spective tables. In total, 242 patients with MLC, of whom 187
hadMLC1, 17 hadMLC2A, and 38 hadMLC2B, were included.
Clinical characteristics
Details are presented in table 1. Macrocephaly in the first year of
life was themost common first disease sign and had been present
in almost all patients in infancy. Macrocephaly persisted in more
than half of patients. Secondary normocephaly was particularly
common in patients with MLC2B. Initial motor development
was reported as mildly delayed in the majority of patients and
normal in a smaller number. All patients except 12 patients with
MLC1 achieved unsupported walking, at a mean age of 16
months (±8, range 10–72). Initial cognitive development was
reported as normal in just over half of patients with MLC1,
MLC2A, and MLC2B. Kaplan-Meier curves on start of motor
deterioration indicated that both patients with MLC1 and
patients with MLC2A showed the first signs of motor de-
terioration at amedian age of 5 years (range 6months–41 years);
there were no significant differences between the curves (p =
0.98; figure 1A). None of the patients withMLC2B had a decline
of motor function; in 34% (10/29), some clumsiness remained.
Loss of walking without support occurred in the majority of
patients with MLC1 and MLC2A at ages ranging from 18
months to 43 years; Kaplan-Meier curves showed no significant
differences between MLC1 and MLC2A (p = 0.66; figure 1B).
Median age at loss of walking without support was estimated to
be 15 years in MLC1 and 11 years in MLC2A. Patients with
MLC2B all remained ambulatory.
Loss of walking with or without support (full wheelchair de-
pendency) occurred in fewer than half of patients with MLC1
and MLC2A and none of the patients with MLC2B. There
were no significant differences between patients with MLC1
and patients withMLC2A (p = 0.58; figure 1C). Patients were
most likely to become wheelchair dependent before the age of
15 years; after this age, patients generally remained ambula-
tory, with or without support.
Behavioral problems were relatively common for all MLC
variants; autism was most common among patients with
MLC2B. Delayed onset cognitive decline was reported in al-
most half of patients with MLC1 andMLC2A, and none of the
patients with MLC2B. However, stable cognitive impairment
was reported in a quarter of patients with MLC2B. The age at
start of cognitive decline did not statistically differ between
MLC1 andMLC2A (log rank p = 0.10). The patients’ cognitive
levels at time of the inventory are presented in table 1.
At the time of clinical phenotyping, 109 patients had had at
least one seizure, of whom the majority had occasional seizures
that were generally well-controlled with medication (table 1).
Kaplan-Meier curve analysis indicated that approximately 75%
of patients with MLC1 and MLC2A had had one or multiple
seizures by age 20 years; the median age at the first seizure was
3 years, mode 2 years (figure 1D). Seizures were less common
among patients with MLC2B (n = 4/34). There were no sig-
nificant differences in onset of seizures between patients with
MLC1 and MLC2A (p = 0.64).
Overview of GMFCS, MACS, and CFCS scores in relation to
age and disease variant showed that there was a wide vari-
ability in clinical severity among patients with MLC1 and
MLC2A (figure 2). Linear regression analysis showed no
significant differences between the patients with MLC1 and
MLC2A regarding GMFCS (p = 0.30), MACS (p = 0.18), and
CFCS scores (p = 0.89). Gross motor function and dexterity
were generally well-preserved in patients with MLC2B and
communication function to a lesser degree.
Several patients with classic MLC had very mild disease: 25%
(17/68) of patients with MLC1 and 45% (5/11) with
MLC2A who were at least 12 years at latest clinical evaluation
were able to walk without support and had normal cognition
or only learning problems. For ages 12 years and above, 32%
(19/59) of patients with MLC1 and 50% (5/10) with
MLC2A had GMFCS, MACS, and CFSC scores of I or II.
Survival was assessed in all 242 patients; 7 were deceased
(figure 1E). Five deceased patients had MLC1: 4 male patients
died at age 7–22 years and 1 female patient at age 56 years.
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Causes of death were respiratory insufficiency after neurologic
deterioration following head trauma, suspected sudden un-
expected death in epilepsy (SUDEP), sepsis as complication of
surgical procedure, cachexia, and status epilepticus. One de-
ceased male patient with MLC2A and 1 deceased male patient
withMLC2B were suspected of SUDEP at ages 23 and 3 years,
respectively.
To assess a possible genotype–phenotype correlation in
patients with MLC1 and MLC2A, we compared loss of am-
bulation, wheelchair dependency, and seizures in groups of
patients with 3 or more patients from 2 or more families with
the same mutations, who were at least 10 years of age at the
clinical inventory. The number of patients with MLC2A was
too small for evaluation. Six groups of informative patients with
MLC1 were available for comparison; characteristics were very
divergent within each group (table e-2, links.lww.com/WNL/
A356), arguing against a genotype–phenotype correlation.
MRI characteristics
MRIs were available for 187 patients and for 53 patients 1
or more follow-up scans were available; we evaluated
a total of 268 MRIs. Patients had their first MRI at
a median age of 2 years (range 4 months–55 years).
Follow-up scans were obtained at a median age of 5 years
(range 11 months–43 years). The median interval be-
tween the first and last MRIs was 4 years (range 3
months–15 years).
Table 1 Clinical characteristics at latest phenotyping
MLC1 MLC2A MLC2B
Study characteristics
No. of patients 187 17 38
Male/female 102/85 9/8 27/11
Median age at latest phenotyping, y (quartiles) 13 (6–19) 15 (7–23) 7 (2–13)
Head circumference, % (n/N)
≥2 SD below age 2 years 99 (121/122) 88 (14/16) 88 (30/34)
Currently ≥2 SD 93 (122/131) 73 (11/15) 56 (15/27)
Walking without support, % (n/N)
Achieved ≤18 mo 63 (88/138) 65 (11/17) 86 (30/35)
Achieved >18 mo 28 (38/138) 35 (6/17) 14 (5/35)
Not achieved 9 (12/138) 0 (0/17) 0 (0/35)
Seizures
No history of seizures 38 (50/132) 31 (5/16) 88 (30/34)
Single seizure 7 (9/132) 19 (3/16) 3 (1/34)
Well-controlled epilepsy 46 (61/132) 44 (7/16) 6 (2/34)
Poorly controlled epilepsy 9 (12/132) 6 (1/16) 3 (1/34)
History of behavioral problems, % (n/N)
Autistic features 9 (8/86) 0 (0/15) 25 (9/36)
Other behavioral problems 29 (31/107) 20 (3/15) 28 (9/32)
Psychiatric diagnosis 14 (15/111) 7 (1/14) 3 (1/30)
Current cognitive function, % (n/N)
Normal 37 (48/129) 31 (5/16) 73 (24/33)
Learning difficulties 21 (27/129) 25 (4/16) 15 (5/33)
Mild mental retardation 26 (34/129) 31 (5/16) 12 (4/33)
Severe mental retardation 16 (20/129) 13 (2/16) 0 (0/33)
Abbreviations: MLC1 = classic megalencephalic leukoencephalopathy with subcortical cysts caused by recessive MLC1 mutations; MLC2A = classic mega-
lencephalic leukoencephalopathy with subcortical cysts caused by recessiveGLIALCAMmutations; MLC2B = remittingmegalencephalic leukoencephalopathy
with subcortical cysts (caused by dominant GLIALCAM mutations).
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Details of the first MRIs are presented in table e-3 (links.lww.
com/WNL/A356). Extensive, confluent signal abnormalities
of the cerebral white matter were invariably present and
swelling was observed in all patients, except for one, in whom
the first MRI was obtained at 30 years. All patients had sparing
of the optic radiation and most patients had sparing in one or
more regions of subcortical white matter (figure 3). Several
patients also had some regional white matter sparing, mostly
in the occipital region (figure 3). There were no clear differ-
ences in abnormalities between patients with MLC1 and
Figure 1 Disease course
Kaplan-Meier plots on (A) onset of motor deterioration, (B) loss of walking without support, (C) loss of walking with or without support (full wheelchair
dependency), (D) onset of seizures, and (E) survival, grouped by disease variant. Censored patients (absence of motor deterioration, still walking without
support, still walking with or without support, absence of seizures, or still alive at last follow-up) are indicated by crosses. MLC1 = classic megalencephalic
leukoencephalopathy with subcortical cysts caused by recessive MLC1 mutations; MLC2A = classic megalencephalic leukoencephalopathy with subcortical
cysts caused by recessive GLIALCAM mutations; MLC2B = remitting megalencephalic leukoencephalopathy with subcortical cysts caused by dominant
GLIALCAM mutations.
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MLC2A. They all had an abnormal signal of the posterior limb
of the internal capsule, while in 54% of patients with MLC2B,
in whom the MRI was obtained before the age of 2 years, the
signal of the internal capsule was already normal (figure 3).
Widening of the ventricles and enlargement of the sub-
arachnoid space was rare in patients with MLC1 and patients
with MLC2A in the early disease stage and more common in
MRIs performed in adolescence or adulthood. In patients
with MLC2B, some enlargement of the subarachnoid spaces
was already observed before the age of 2 years in nearly half of
patients.
Subcortical cysts were present in all patients with MLC1 and
almost all patients with MLC2A. Forty-three percent of patients
with MLC2B did not have true cysts, but only near-cystic rare-
faction of subcortical white matter. Cysts or near-cystic rarefac-
tion were almost invariably present in both anterior temporal
lobes. Additional cysts were located in the frontal and parietal
lobes, but never in the occipital lobe. Near-cystic rarefaction of
subcortical white matter could be located in all 4 lobes.
The majority of patients with MLC1 and patients with
MLC2A (;85%) had mild signal abnormalities of the cere-
bellar white matter, which were less pronounced than the
cerebral white matter signal abnormalities (figure 3). Patients
with MLC2B never had cerebellar white matter signal ab-
normalities; a few patients younger than 10 months showed
some delay in myelination featured by a hyperintense rim of
the subcortical cerebellar white matter (figure e-1, links.lww.
com/WNL/A355). The cerebellar white matter was never
swollen. Almost all patients with MLC1, MLC2A, and
MLC2B had mild signal abnormalities in the brainstem.
Change over time
Details are presented in table 2. Normalization of the signal
and reversal of the swelling of the white matter only occurred
in patients with MLC2B. In patients with MLC1 and patients
with MLC2A, the white matter signal abnormalities persisted
or increased, with the exception of 2 patients with MLC1 who
showed improvement. The number of cysts generally
remained the same or increased among patients with MLC1
and MLC2A; in MLC2B, a decrease of cysts and overall
quantity of cystic white matter generally occurred, although in
all but one patient some cysts or near-cysts persisted.
Existing signal abnormalities of the posterior limb of the in-
ternal capsule and cerebellar white matter never improved in
patients with MLC1 and MLC2A. The few patients with
MLC2B who had a rim of slightly abnormal cerebellar white
matter on the initial MRI all showed normalization over time.
Discussion
MLC is caused by mutations inMLC1 or GLIALCAM. MLC1
is an astrocyte-specific membrane protein involved in brain ion
and water homeostasis.3,17 GlialCAM is a chaperone of MLC1
ensuring its localization in astrocytic endfeet.7,18,19 So, both
MLC1 and GLIALCAM mutations affect MLC1 protein
function. In addition, GlialCAM is involved in transport of
other proteins, such as connexin 43 and the chloride channel
ClC2.20,21 Recessive CLCN2 mutations cause a leukoence-
phalopathy with childhood or adult onset, characterized by
mild motor dysfunction and often retinopathy.22 Brain MRI
shows restricted diffusion in the posterior limbs of internal
capsules, brainstem structures, and cerebellar white matter,
suggestive of myelin microvacuolization.22 Pediatric patients
have diffuse, mild cerebral white matter signal abnormalities,
while these are limited in adult-onset cases. By contrast, in
MLC the cerebral white matter abnormalities are profound and
diffusion is highly increased, consistent with myelin macro-
vacuolization and increased extracellular spaces.23 Considering
that GlialCAM is supposed to be a chaperone for both MLC1
and ClC2, one might expect GLIALCAM mutations to cause
disease features of both MLC1- and CLCN2-associated
Figure 2 Function levels
Overview of megalencephalic leukoencephalopathy with subcortical cysts
(MLC) patients’ scores on (A) the Gross Motor Function Classification System
(GMFCS), (B) Manual Ability Classification System (MACS), and (C) Commu-
nication Function Classification System (CFCS) in relation to age, grouped by
disease variant: MLC1 (classic MLC caused by recessive MLC1 mutations;
blue circles), MLC2A (classic MLC caused by recessive GLIALCAMmutations;
red squares) and MLC2B (remitting MLC caused by dominant GLIALCAM
mutations; green triangles). Scores range from I (no limitations) to V (severe
limitations; table e-1, links.lww.com/WNL/A356).
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diseases. The present study, however, confirms that MLC2A is
indistinguishable fromMLC1 and by nomeans shares theMRI
features of the CLCN2-related disease. The exact roles of
MLC1, GlialCAM, and ClC2 in brain ion and water homeo-
stasis and their interaction remain to be elucidated.
The knowledge obtained fromour study concerning a relatively
large cohort of patients can help physicians in clinical coun-
seling of patients and families. MLC is a fairly mild and slow
disorder, with low mortality compared to other leukodystro-
phies.24 Nevertheless, there is a rather broad variation in clinical
severity. Some patients become wheelchair-dependent a few
years after onset, while others remain ambulatory during
adulthood. An interesting point is that slow motor de-
terioration often occurs from a few years after presentation
onwards, but that patients who are ambulatory with or without
support at the age of 15 years most likely remain ambulatory.
The study confirms that epilepsy is a common feature in
MLC.25 It is puzzling that most patients have well-controlled
epilepsy while few patients have refractory epilepsy and;25%
remain seizure-free. A salient observation is that a considerable
proportion of patients with classic MLC exhibit only very mild
signs during the disease course; in 2 patients with MLC1,
a considerable improvement of the MRI abnormalities oc-
curred. The observed variability in disease severity—also
among patients who share the same mutations—may depend
on individual differences in compensatory volume regulatory
mechanisms. The fact that remarkable improvement of cerebral
swelling may occur, as mostly observed in patients with
MLC2B but also in a few patients with classic MLC, suggests
there is a window of opportunity for therapy.
The multi-institutional and observational nature of this study
comes with certain limitations. In the absence of formal test-
ing, measures like cognitive function and presence of autistic
features were scored based on subjective assessment by
Figure 3MRI characteristics
MRI findings in a patient with mega-
lencephalic leukoencephalopathy
with subcortical cysts (MLC) caused
by recessive MLC1 mutations (MLC1)
at age 3 years (top), a patient with
MLC caused by recessive GLIALCAM
mutations (MLC2A) at age 6 years
(middle), and a patient with MLC
caused by dominant GLIALCAM
mutations (MLC2B) at age 10months
(bottom). Sagittal T1-weighted
images show anterior-temporal and
frontoparietal cysts in the patient
with MLC1 (A), an anterior-temporal
cyst in the patient with MLC2A (D),
and some near-cystic rarefaction in
the anterior-temporal region in the
patient with MLC2B (G). The T2-
weighted axial images of the hemi-
spheres show diffuse white matter
abnormalities with some swelling (B,
E, H). The sagittal images show some
sparing of the subcortical white
matter in all patients, especially in
the occipital region (A, D, G); in the
patient withMLC2B, thewhitematter
is relatively preserved in the occipital
region (G). The patients with classic
MLC have a double-line-shaped ab-
normal signal of the posterior limb of
the internal capsule (B, E), while the
signal is normal in the patient with
MLC2B (H). The T2-weighted axial
images of the cerebellum show
a mildly hyperintense signal of the
cerebellar white matter in the
patients with classic MLC (C, F) and
a normal signal in the patient with
MLC2B (I).
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physicians and caretakers. The application of time-to-event
analysis and standardized scales such as GMFCS resulted in
a robust representation of disease progression, but missing
data and interobserver differences may have hampered the
evaluation of the clinical course. There are, however, no
indications that nonresponse was in any way systematic or that
censoring in the time-to-event analyses was informative. The
study limitations are at least in part compensated by the study
size considering the disease is very rare. The available results
give an already informative delineation of the clinical spectrum
of MLC. Our ongoing data collection will help include larger
numbers of patients with MLC2A and extend the follow-up.
Table 2 MRI characteristics: Change over time
MLC1 MLC2A MLC2B
No. of patients 29 5 19
Median interval (range) 4 y (3 mo–13 y) 13 y (1–15 y) 3 y (4 mo–12 y)
Swelling cerebral WM, % (n/N)
Normalization 0 (0/29) 0 (0/5) 11 (2/19)
Improvement 21 (6/29) 40 (2/5) 78 (15/19)
Unchanged 79 (23/29) 40 (2/5) 11 (2/19)
Increased 0 (0/29) 20 (1/5) 0 (0/19)
Signal abnormalities cerebral WM, % (n/N)
Normalization 0 (0/29) 0 (0/5) 21 (4/19)
Improvement 6 (2/29) 0 (0/5) 74 (14/19)
Unchanged 73 (21/29) 40 (2/5) 5 (1/19)
Increased 21 (6/29) 60 (3/5) 0 (0/19)
Signal abnormalities PLIC, % (n/N)
Not present 0 (0/26) 0 (0/5) 47 (9/19)
Normalization 0 (0/26) 0 (0/5) 26 (5/19)
Improvement 8 (2/26) 0 (0/5) 11 (2/19)
Unchanged 92 (24/26) 100 (5/5) 16 (3/19)
Enlargement ventricles or subarachnoid spaces, % (n/N)
Not present 72 (21/29) 40 (2/5) 53 (10/19)
Unchanged 4 (1/29) 0 (0/5) 0 (0/19)
Increased 24 (7/29) 60 (3/5) 47 (9/19)
No. of cysts, % (n/N)
Not present 0 (0/27) 0 (0/5) 37 (7/19)
Decreased 4 (1/27) 0 (0/5) 42 (8/19)
Unchanged 67 (18/27) 40 (2/5) 21 (4/19)
Increased 29 (8/27) 60 (3/5) 0 (0/19)
Signal abnormalities cerebellar WM, % (n/N)
Not present 11 (3/28) 40 (2/5) 89 (17/19)
Normalization 3 (1/28) 0 (0/5) 11 (2/19)
Decreased 0 (0/28) 0 (0/5) 0 (0/19)
Unchanged 86 (24/28) 60 (3/5) 0 (0/19)
Abbreviations: MLC1 = classic megalencephalic leukoencephalopathy with subcortical cysts caused by recessive MLC1 mutations; MLC2A = classic mega-
lencephalic leukoencephalopathy with subcortical cysts caused by recessiveGLIALCAMmutations; MLC2B = remittingmegalencephalic leukoencephalopathy
with subcortical cysts caused by dominant GLIALCAM mutations; PLIC = posterior limb of the internal capsule; WM = white matter.
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One of the aims of this study was to identify features that can
help distinguish different MLC variants in early disease stages.
Absence of MRI signal abnormalities of the posterior limb of
the internal capsule and cerebellar white matter and presence
of only rarefied subcortical white matter instead of actual cysts
are features suggestive of MLC2B. This knowledge can be
applied to direct genetic testing in patients suspected of the
remitting phenotype. No distinguishing features have been
identified to discern MLC1 and MLC2A. Considering the
much higher prevalence of MLC1 gene defects, in cases of
a classic presentation of MLC, this gene should be tested first.
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Study question
Are there clinical and MRI characteristics that can distinguish
the different subtypes of megalencephalic leukoencephalop-
athy with subcortical cysts (MLC)?
Summary answer
MRI findings can distinguish classic MLC from remitting
MLC, but distinguishing classic MLC variants resulting from
mutations in different genes is not possible.
What is known and what this paper adds
MLC is a rare disorder with classic forms caused by recessive
MLC1mutations (theMLC1 subtype) or recessiveGLIALCAM
mutations (the MLC2A subtype) and a remitting form caused
by dominant GLIALCAM mutations (the MLC2B subtype).
This study provides evidence that MRI findings can distinguish
the MLC2B subtype from the MLC2A and MLC1 subtypes.
Participants and setting
This study analyzed data for 204 patients with classic MLC,
including 187 with the MLC1 subtype and 17 with the
MLC2A subtype, and 38 patients with the remitting MLC2B
subtype. These patients were listed in the Amsterdam Data-
base, which catalogs genetically proven MLC cases from
around the world, between January 1991 and January 2017.
Design, size, and duration
The patients’ clinical and MRI data were reviewed by clini-
cians at the Vrije Universiteit Amsterdam Medical Center.
Clinical data were obtained by sending questionnaires to the
patients’ primary physicians and reviewing medical records.
Primary outcomes
The primary outcome was the identification of variables that
differed between the MLC subtypes.
Main results and the role of chance
No clinical or MRI variables distinguished the MLC1 subtype
from theMLC2A subtype. Relative to theMLC1 andMLC2A
subtypes, the MLC2B subtype was associated with a milder
clinical presentation, including preservation of motor func-
tions, the absence of delayed-onset cognitive decline, and
a lower likelihood of seizures. The MLC2B subtype was also
associated with distinctive MRI findings, including mild sub-
arachnoid space enlargement before 2 years of age, a lower
likelihood of true cysts, the absence of cerebellar white matter
signal abnormalities, and signal normalization and reversal of
white matter swelling over time.
Bias, confounding, and other reasons
for caution
Cognitive assessments relied on subjective assessments rather
than formal testing. Missing data and inter-observer differ-
ences might have introduced bias.
Generalizability to other populations
Given the rarity of the disease, this study had a large and
diverse sample, which favors the generalizability of the results.
Study funding/potential competing interests
This study was funded by the Optimix Foundation for Sci-
entific Research. The authors report no competing interests.
Go to Neurology.org/N for full disclosures.
Table Longitudinal changes in cerebral white matter
signal abnormalities in cases with adequate MRI
data
Change Classic MLC Remitting MLC
Normalization 0% (0/34) 21% (4/19)
Improvement 6% (2/34) 74% (14/19)
No change 68% (23/34) 5% (1/19)
Increase 26% (9/34) 0% (0/19)
Abbreviation: MLC = megalencephalic leukoencephalopathy with sub-
cortical cysts.
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